Currently, the Luxturna RPE65 gene augmentation therapy is being used to treat patients with Leber congenital amaurosis (LCA) and retinitis pigmentosa (RP) carrying RPE65 variants [1,2]. This evidence concerns the gene RPE65 and Leber congenital amaurosis.